Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0661232/Osteoporosis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The expected moderate growth can be attributed to the increase in awareness, an ageing population and the launch of prominent pipeline molecules such as Odanacatib (MK-0822) and NB S101. The impending patent expiry of Boniva (ibandronate) in 2012; Actonel (risedronate sodium) and Reclast (zoledronic acid) in 2013; and Evista (raloxifene) in 2014 will lead to patients having access to treatment at much lower prices reflecting brand erosion of these drugs. The growth in the historic period was also affected by Fosamax (alendronate) generics, which lost its patent exclusivity in 2008.
Scope
The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor
- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global osteoporosis therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Osteoporosis Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Disease Burden 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Signs and Symptoms 12
2.7 Diagnosis 13
2.7.1 Physical Examination 13
2.7.2 Medical History 13
2.7.3 BMD Testing 14
2.7.4 Laboratory Tests 15
2.8 Treatment and Management Options 16
2.9 GlobalData Pipeline Report Guidance 19
3 Osteoporosis Therapeutics - Market Characterization 20
3.1 Osteoporosis Therapeutics Market Size (2005-2010) - Global 20
3.2 Osteoporosis Therapeutics Market Forecast (2010-2018) - Global 21
3.3 Osteoporosis Therapeutics Market Size (2005-2010) - The US 23
3.4 Osteoporosis Therapeutics Market Forecast (2010-2018) - The US 24
3.5 Osteoporosis Therapeutics Market Size (2005-2010) - France 25
3.6 Osteoporosis Therapeutics Market Forecast (2010-2018) - France 26
3.7 Osteoporosis Therapeutics Market Size (2005-2010) - Germany 27
3.8 Osteoporosis Therapeutics Market Forecast (2010-2018) - Germany 28
3.9 Osteoporosis Therapeutics Market Size (2005-2010) - Italy 29
3.10 Osteoporosis Therapeutics Market Forecast (2010-2018) - Italy 30
3.11 Osteoporosis Therapeutics Market Size (2005-2010) - Spain 31
3.12 Osteoporosis Therapeutics Market Forecast (2010-2018) - Spain 32
3.13 Osteoporosis Therapeutics Market Size (2005-2010) - The UK 33
3.14 Osteoporosis Therapeutics Market Forecast (2010-2018) - The UK 34
3.15 Osteoporosis Therapeutics Market Size (2005-2010) - Japan 35
3.16 Osteoporosis Therapeutics Market Forecast (2010-2018) - Japan 36
3.17 Drivers and Barriers for the Osteoporosis Therapeutics Market 37
3.17.1 Drivers for the Osteoporosis Therapeutics Market 37
3.17.2 Barriers for the Osteoporosis Therapeutics Market 38
3.18 Opportunity and Unmet Need 39
3.19 Key Takeaway 41
4 Osteoporosis Therapeutics - Competitive Assessment 42
4.1 Overview 42
4.2 Strategic Competitor Assessment 42
4.3 Product Profile for the Major Marketed Products in the Osteoporosis Therapeutics Market 44
4.3.1 Fosamax (alendronate sodium) 44
4.3.2 Actonel (risedronate sodium) 45
4.3.3 Boniva (ibandronate sodium) 47
4.3.4 Reclast (zoledronic acid) 49
4.3.5 Evista (raloxifene hydrochloride) 50
4.3.6 Prolia (denosumab) 52
4.3.7 Forteo (teriparatide [rDNA origin]) injection 53
4.3.8 Miacalcin (salmon calcitonin) 55
4.3.9 Activella (estradiol, norethindrone acetate) 55
4.3.10 Premarin (estrogen) 57
4.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate) 57
4.3.12 Fablyn (lasofoxifene) 58
4.3.13 Viviant (bazedoxifene) 59
4.4 Key Takeaway 60
5 Osteoporosis Therapeutics - Pipeline Assessment 61
5.1 Overview 61
5.2 Strategic Pipeline Assessment 61
5.3 Osteoporosis Therapeutics - Pipeline Analysis by Clinical Phase of Development 61
5.3.1 Osteoporosis Therapeutics - Phase III and Regulatory Filed Clinical Pipeline 62
5.3.2 Osteoporosis Therapeutics - Phase II Clinical Pipeline 63
5.3.3 Osteoporosis Therapeutics - Phase I Clinical Pipeline 63
5.3.4 Osteoporosis Therapeutics - Preclinical Phase Pipeline 64
5.4 Osteoporosis Therapeutics - Pipeline by Mechanism of Action 65
5.5 Technology Trends Analytical Framework 66
5.6 Osteoporosis Therapeutics - Most Promising Drugs in Clinical Development 67
5.7 Most Promising Drugs in Clinical Development 68
5.7.1 Aprela 68
5.7.2 EX101 68
5.7.3 Odanacatib (MK-0822) 69
5.7.4 NB S101 70
5.7.5 SMC 021 70
5.7.6 Ostora 71
5.7.7 BA058- injection 72
5.7.8 UNI-PH (1-34), rhPTH 1-34 72
5.7.9 YM529/ONO-5920 - Astellas/ONO 72
5.8 Key Takeaway 73
6 Osteoporosis Therapeutics - Clinical Trials Mapping 74
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 74
6.2 Clinical Trials by Phase of Clinical Development 75
6.3 Clinical Trials by Trial Status 76
6.4 Prominent Sponsors 77
6.5 Clinical Trials by Sponsors 78
6.6 Top Companies Participating in Osteoporosis Therapeutics Clinical Trials 79
7 Osteoporosis Therapeutics - Strategic Assessment 80
7.1 Key Events Impacting the Future Market 80
7.2 Future Market Competition Scenario 81
8 Osteoporosis Therapeutics - Future Players 83
8.1 Introduction 83
8.2 Company Profiles 84
8.2.1 Amgen Inc. 84
8.2.2 Astellas Pharma, Inc. 86
8.2.3 EffRx, Inc. 88
8.2.4 Merck & Co. Inc. 88
8.2.5 Novartis AG 89
8.2.6 Osteologix, Inc. 91
8.2.7 Pfizer Inc. 92
8.2.8 Radius Health, Inc 94
8.2.9 Tarsa Inc. 94
8.2.10 Zydus Cadila Healthcare Limited 95
8.3 Other Companies in the Osteoporosis Therapeutics Market 97
8.4 Key Takeaway 99
9 Osteoporosis Therapeutics - Licensing & Partnership Deals 100
10 Osteoporosis Therapeutics - Appendix 110
10.1 Market Definitions 110
10.2 Abbreviations 110
10.3 Research Methodology 111
10.3.1 Coverage 112
10.3.2 Secondary Research 112
10.3.3 Forecasting 112
10.3.4 Primary Research 115
10.3.5 Expert Panel Validation 115
10.4 Contact Us 115
10.5 Disclaimer 115
10.6 Bibliography 116
List of Tables
Table 1: Difference Between Type I and Type II Osteoporosis 8
Table 2: Osteoporosis Prevalence and Low Bone Mass in People Aged 50 and Over in the US (Million)* 9
Table 3: Difference Between Diagnostic Techniques Used for BMD Measurement 14
Table 4: WHO Classification for Diagnosis of Osteoporosis Using BMD Measurements 15
Table 5: Approved Drugs for the Prevention and Treatment of Postmenopausal Osteoporosis 17
Table 6: Dosage Schedule for Drugs Used for the Treatment of Osteoporosis 18
Table 7: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
Table 8: Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010-2018 22
Table 9: Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005-2010 23
Table 10: Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010-2018 24
Table 11: Osteoporosis Therapeutics Market, France, Revenue ($bn), 2005-2010 25
Table 12: Osteoporosis Therapeutics Market, France, Forecast ($bn), 2010-2018 26
Table 13: Osteoporosis Therapeutics Market, Germany, Revenue ($bn), 2005-2010 27
Table 14: Osteoporosis Therapeutics Market, Germany, Forecast ($bn), 2010-2018 28
Table 15: Osteoporosis Therapeutics Market, Italy, Revenue ($bn), 2005-2010 29
Table 16: Osteoporosis Therapeutics Market, Italy, Forecast ($bn), 2010-2018 30
Table 17: Osteoporosis Therapeutics Market, Spain, Revenue ($bn), 2005-2010 31
Table 18: Osteoporosis Therapeutics Market, Spain, Forecast ($bn), 2010-2018 32
Table 19: Osteoporosis Therapeutics Market, The UK, Revenue ($bn), 2005-2010 33
Table 20: Osteoporosis Therapeutics Market, The UK, Forecast ($bn), 2010-2018 34
Table 21: Osteoporosis Therapeutics Market, Japan, Revenue ($bn), 2005-2010 35
Table 22: Osteoporosis Therapeutics Market, Japan, Forecast ($bn), 2010-2018 36
Table 23: Effect of Actonel on the Risk of Vertebral Fractures 47
Table 24: Effect of Evista on Risk of Vertebral Fractures 51
Table 25: Effect of Evista on Increases in BMD vs. Placebo 52
Table 26: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 54
Table 27: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis 54
Table 28: Osteoporosis Therapeutics Market, Phase III and Regulatory Filed Pipeline, 2011 62
Table 29: Osteoporosis Therapeutics Market, Phase II Pipeline, 2011 63
Table 30: Osteoporosis Therapeutics Market, Phase I Pipeline, 2011 63
Table 31: Osteoporosis Therapeutics Market, Preclinical Phase Pipeline, 2011 64
Table 32: Osteoporosis Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011 67
Table 33: Osteoporosis Therapeutics, Global, Clinical Trials, 2011 74
Table 34: Osteoporosis Therapeutics, Global, Clinical Trials by Phase, 2011 75
Table 35: Osteoporosis Therapeutics, Global, Clinical Trials by Status of Development, 2011 76
Table 36: Osteoporosis Therapeutics, Global, Prominent Sponsors, 2011 77
Table 37: Osteoporosis Therapeutics, Global, Overall Sponsors, 2011 78
Table 38: Osteoporosis Therapeutics, Global, Top Ten Companies by Phase, 2011 79
Table 39: Amgen Inc.- Osteoporosis Pipeline, 2011 85
Table 40: Astellas Pharma, Inc. - Osteoporosis Pipeline, 2011 87
Table 41: EffRx, Inc. - Osteoporosis Pipeline, 2011 88
Table 42: Merck & Co., Inc.- Osteoporosis Pipeline, 2011 89
Table 43: Novartis AG - Osteoporosis Pipeline, 2011 91
Table 44: Osteologix,Inc. - Osteoporosis Pipeline, 2011 91
Table 45: Pfizer Inc. - Osteoporosis Pipeline, 2011 94
Table 46: Radius Health Inc. - Osteoporosis Pipeline, 2011 94
Table 47: Tarsa Inc. - Osteoporosis Pipeline, 2011 95
Table 48: ZydusCadila Inc. - Osteoporosis Pipeline, 2011 96
Table 49: Osteoporosis Therapeutics Market - Future Players 97
Table 50: Osteoporosis Therapeutics, Global, Deals - 2011 100
List of Figures
Figure 1: Micro-architecture of Osteoporotic and Normal Bone 7
Figure 2: Classification of Osteoporosis 8
Figure 3: Image Depicting Osteoporotic Bone Condition 11
Figure 4: Common Fracture Sites 12
Figure 5: Treatment Algorithm for Osteoporosis 16
Figure 6: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2005-2010 20
Figure 7: Osteoporosis Therapeutics Market, Global, Forecast ($bn), 2010-2018 21
Figure 8: Osteoporosis Therapeutics Market, The US, Revenue ($bn), 2005-2010 23
Figure 9: Osteoporosis Therapeutics Market, The US, Forecast ($bn), 2010-2018 24
Figure 10: Osteoporosis Therapeutics Market, France, Revenue ($bn), 2005-2010 25
Figure 11: Osteoporosis Therapeutics Market, France, Forecast ($bn), 2010-2018 26
Figure 12: Osteoporosis Therapeutics Market, Germany, Revenue ($bn), 2005-2010 27
Figure 13: Osteoporosis Therapeutics Market, Germany, Forecast ($bn), 2010-2018 28
Figure 14: Osteoporosis Therapeutics Market, Italy, Revenue ($bn), 2005-2010 29
Figure 15: Osteoporosis Therapeutics Market, Italy, Forecast ($bn), 2010-2018 30
Figure 16: Osteoporosis Therapeutics Market, Spain, Revenue ($bn), 2005-2010 31
Figure 17: Osteoporosis Therapeutics Market, Spain, Forecast ($bn), 2010-2018 32
Figure 18: Osteoporosis Therapeutics Market, The UK, Revenue ($bn), 2005-2010 33
Figure 19: Osteoporosis Therapeutics Market, The UK, Forecast ($bn), 2010-2018 34
Figure 20: Osteoporosis Therapeutics Market, Japan, Revenue ($bn), 2005-2010 35
Figure 21: Osteoporosis Therapeutics Market, Japan, Forecast ($bn), 2010-2018 36
Figure 22: Opportunity and Unmet Need in the Osteoporosis Therapeutics Market 40
Figure 23: Strategic Competitor Assessment of the Marketed Products in Osteoporosis Therapeutics, 2011 43
Figure 24: Osteoporosis Therapeutics Pipeline by Phase of Clinical Development, 2011 61
Figure 25: Osteoporosis Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 65
Figure 26: Technology Trends Analytics Framework, 2011 66
Figure 27: Technology Trends Analytics Frame Work - Description, 2011 67
Figure 28: Osteoporosis Therapeutics, Global, Clinical Trials by Country, 2011 74
Figure 29: Osteoporosis Therapeutics, Global, Clinical Trials by Phase (%), 2011 75
Figure 30: Osteoporosis Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 76
Figure 31: Osteoporosis Therapeutics, Global, Prominent Sponsors (%), 2011 77
Figure 32: Osteoporosis Therapeutics, Global, Overall Sponsors (%), 2011 78
Figure 33: Osteoporosis Therapeutics, Global, Top Ten Companies by Phase, 2011 79
Figure 34: Osteoporosis Therapeutics Market, Drivers and Restraints, 2011 80
Figure 35: Implications for Future Market Competition in the Osteoporosis Therapeutics Market, 2011 81
Figure 36: Osteoporosis Therapeutics Market, Global, Future Players, 2011 83
Figure 37: GlobalData Market Forecasting Model 114
Companies mentioned
Amgen Inc.
Astellas Pharma, Inc.
EffRx, Inc.
Merck & Co. Inc.
Novartis AG
Osteologix, Inc.
Pfizer Inc.
Radius Health, Inc
Tarsa Inc.
Zydus Cadila Healthcare Limited
To order this report:
Therapy Industry: Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article